KTD-092 is a hit for DYRK1A inhibition, with an IC50 of 22 nM for human DYRK1A. KTD-092 can be used in the research for Down syndrome (DS), Alzheimers disease (AD), autism spectrum disorder (ASD), diabetes and other neurodegenerative diseases[1].
Molecular Weight:
383.40
Formula:
C19H21N5O4
Target:
DYRK
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
